Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure
Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure
复制标题
DOI：
10.1161/01.cir.94.11.2807
复制
发表时间：
1996-12-01
期刊：
影响因子：
37.8
通讯作者：
Shusterman, N
中科院分区：
文献类型：
--
作者：
Bristow, MR;Gilbert, EM;Shusterman, N
背景：我们进行了一项多中心的安慰剂对照试验，旨在确定卡维地洛的有效性和安全性。卡维地洛是一种具有血管扩张剂特性的第三代β阻滞剂。方法和结果345例轻、中度、稳定的慢性心力衰竭患者被随机分为4组，分别接受安慰剂、6.25mgBid卡维地洛(低剂量组)、12.5mgBid卡维地洛(中剂量组)或25mgBid卡维地洛(高剂量组)治疗。在2到4周的上升滴定期后，受试者继续接受为期6个月的研究药物治疗。主要的疗效参数是通过两种不同的技术测量的次极量运动，即6分钟的走廊步行试验和9分钟的自动跑步机试验。卡维地洛对任何一种技术测量的次极量运动都没有可检测到的影响。然而，卡维地洛与剂量相关的左心功能改善有关(与安慰剂组的2个射血分数单位相比，低、中、高剂量卡维地洛组分别增加了5、6和8个射血分数单位，P
Background We conducted a multicenter, placebo-controlled trial designed to establish the efficacy and safety of carvedilol, a ''third-generation'' beta-blocking agent with vasodilator properties, in chronic heart failure.Methods and Results Three hundred forty-five subjects with mild to moderate, stable chronic heart failure: were randomized to receive treatment with placebo, 6.25 mg BID carvedilol (low-dose group), 12.5 mg BID carvedilol (medium-dose group), or 25 mg BID carvedilol (high-dose group). After a 2- to 4-week up-titration period, subjects remained on study medication for a period of 6 months. The primary efficacy parameter was submaximal exercise measured by two different techniques, the 6-minute corridor walk test and the 9-minute self-powered treadmill test. Carvedilol had no detectable effect on submaximal exercise as measured by either technique. However, carvedilol was associated with dose-related improvements in LV function (by 5, 6, and 8 ejection fraction [EF] units in the low-, medium-, and high-dose carvedilol groups, respectively, compared with 2 EF units with placebo, P